[Results of a long-term study with acemetacin in the therapy of patients suffering from rheumatoid arthritis (author's transl)].

Within the framework of a long-term study the efficacy and tolerability of [1-(p-chlorobenzoyl)-5-methoxy-2-methylindol-3-acetoxy] acetic acid (acemetacin, TV 1322, Rantudil) were tested in 26 female patients suffering from rheumatoid arthritis. The patients were aged between 32 and 78 years. The duration of therapy was 24 weeks.

[Controlled double blind comparison of acemetacin to indomethacin in patients with chronic polyarthritis].

In a double blind study [1-(p-chlorobenzoyl)-5-methoxy-2-methylindol-3-acetoxy] acetic acid (acemetacin, TV 1322, Rantudil¿) was compared with indometacin in 2 x 20 patients suffering from rheumatoid arthritis. The duration of the study was 3 weeks. The patients received 3 x 30 mg/d acemetacin or 3 x 50 mg indometacin in capsules.

[Influence of acemetacin on DNA repair and DNA synthesis in vitro and in vivo (author's transl)].

The effects of [1-(p-chlorobenzoyl)-5-methoxy-2-methyl-indole-3-acetoxy]-acetic acid (acemetacin, TV 1322, Rantudil) on DNA repair (unscheduled DNA synthesis) and semiconservative DNA synthesis have been investigated in vitro in mouse spleen cells and in vivo in human leukocytes. Quantitative determination of DNA repair was made possible by a computer program and additional measurement of parameters of uptake kinetics. in vitro results showed no influence on DNA synthesis and therapeutically relevant concentrations had no influence on DNA repair.